Citigroup Inc. purchased a new position in Strongbridge Biopharma PLC (NASDAQ:SBBP) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 47,241 shares of the biotechnology company’s stock, valued at approximately $338,000. Citigroup Inc. owned about 0.13% of Strongbridge Biopharma PLC at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. State of Wisconsin Investment Board purchased a new position in shares of Strongbridge Biopharma PLC in the second quarter worth $114,000. Rhumbline Advisers purchased a new position in shares of Strongbridge Biopharma PLC in the second quarter worth $154,000. Teachers Advisors LLC purchased a new position in shares of Strongbridge Biopharma PLC in the second quarter worth $297,000. Bank of New York Mellon Corp purchased a new position in shares of Strongbridge Biopharma PLC in the second quarter worth $331,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of Strongbridge Biopharma PLC in the second quarter worth $332,000. 56.48% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/citigroup-inc-invests-338000-in-strongbridge-biopharma-plc-sbbp/1635990.html.

A number of research firms have issued reports on SBBP. Zacks Investment Research raised shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating and set a $7.25 price target for the company in a report on Wednesday, October 11th. ValuEngine cut shares of Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Oppenheimer Holdings, Inc. started coverage on shares of Strongbridge Biopharma PLC in a report on Thursday, August 10th. They issued an “outperform” rating and a $12.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $11.81.

Strongbridge Biopharma PLC (NASDAQ SBBP) opened at 6.25 on Tuesday. The company’s 50 day moving average is $6.66 and its 200 day moving average is $5.79. Strongbridge Biopharma PLC has a one year low of $2.00 and a one year high of $8.85. The stock’s market cap is $220.84 million.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $0.84 million. On average, equities research analysts expect that Strongbridge Biopharma PLC will post ($2.48) EPS for the current year.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Institutional Ownership by Quarter for Strongbridge Biopharma PLC (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.